628
Views
8
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ligelizumab for the treatment of chronic spontaneous urticaria

ORCID Icon
Pages 853-861 | Received 26 Mar 2020, Accepted 06 May 2020, Published online: 19 May 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Bettina Wedi. (2022) Emerging treatments for chronic urticaria. Expert Opinion on Investigational Drugs 31:3, pages 281-290.
Read now
Bettina Wedi & Stephan Traidl. (2021) Anti-IgE for the Treatment of Chronic Urticaria. ImmunoTargets and Therapy 10, pages 27-45.
Read now

Articles from other publishers (6)

Filomena Russo, Giulio Cortonesi, Laura Lazzeri, Paolo Taddeucci & Pietro Rubegni. (2022) A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Dermatologic Therapy 35:11.
Crossref
Sara Manti, Alessandro Giallongo, Maria Papale, Giuseppe Fabio Parisi & Salvatore Leonardi. (2022) Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease. Journal of Clinical Medicine 11:15, pages 4453.
Crossref
Olguța Anca Orzan, Liliana Gabriela Popa, Mara Mădălina Mihai, Anca Cojocaru, Călin Giurcăneanu & Alexandra Maria Dorobanțu. (2022) Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies. Medicina 58:6, pages 816.
Crossref
Attila Gábor Szöllősi, Attila Oláh, Erika Lisztes, Zoltán Griger & Balázs István Tóth. (2022) Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk. Frontiers in Pharmacology 13.
Crossref
Sujoy Khan, Charu Chopra, Alaistair Mitchell, Alla Nakonechna, Patrick Yong & Mohammed Yousuf Karim. (2022) Resistant Chronic Spontaneous Urticaria – A Case Series Narrative Review of Treatment Options. Allergy & Rhinology 13, pages 215265752211449.
Crossref
Young-Min Ye. 2021. Urticaria - Diagnosis and Management. Urticaria - Diagnosis and Management.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.